This company has been marked as potentially delisted and may not be actively trading.

Day One Biopharmaceuticals (DAWN) Competitors

DAWN vs. IBRX, NUVL, PCVX, QGEN, and KYMR

Should you buy Day One Biopharmaceuticals stock or one of its competitors? MarketBeat compares Day One Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Day One Biopharmaceuticals include ImmunityBio (IBRX), Nuvalent (NUVL), Vaxcyte (PCVX), Qiagen (QGEN), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Day One Biopharmaceuticals compare to ImmunityBio?

Day One Biopharmaceuticals (NASDAQ:DAWN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Day One Biopharmaceuticals has a beta of -1.74, suggesting that its share price is 274% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Day One Biopharmaceuticals has higher revenue and earnings than ImmunityBio. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Day One Biopharmaceuticals	$158.18M	14.06	-$107.32M	-$1.03	N/A
ImmunityBio	$113.29M	75.35	-$351.40M	-$0.85	N/A

Day One Biopharmaceuticals has a net margin of -67.85% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Day One Biopharmaceuticals	-67.85%	-23.43%	-20.69%
ImmunityBio	-606.15%	N/A	-59.53%

Day One Biopharmaceuticals currently has a consensus target price of $23.29, indicating a potential upside of 8.15%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 74.23%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Day One Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Day One Biopharmaceuticals	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, ImmunityBio had 59 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 59 mentions for ImmunityBio and 0 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.94 beat ImmunityBio's score of 0.12 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Day One Biopharmaceuticals	Positive
ImmunityBio	Neutral

88.0% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Comparatively, 69.5% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ImmunityBio beats Day One Biopharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Day One Biopharmaceuticals compare to Nuvalent?

Day One Biopharmaceuticals (NASDAQ:DAWN) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Day One Biopharmaceuticals has higher revenue and earnings than Nuvalent. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Day One Biopharmaceuticals	$158.18M	14.06	-$107.32M	-$1.03	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -67.85%. Day One Biopharmaceuticals' return on equity of -23.43% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Day One Biopharmaceuticals	-67.85%	-23.43%	-20.69%
Nuvalent	N/A	-40.11%	-35.43%

Day One Biopharmaceuticals has a beta of -1.74, suggesting that its share price is 274% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, Nuvalent had 16 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 16 mentions for Nuvalent and 0 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.94 beat Nuvalent's score of 0.19 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Day One Biopharmaceuticals	Positive
Nuvalent	Neutral

Day One Biopharmaceuticals currently has a consensus target price of $23.29, indicating a potential upside of 8.15%. Nuvalent has a consensus target price of $137.25, indicating a potential upside of 30.44%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts plainly believe Nuvalent is more favorable than Day One Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Day One Biopharmaceuticals	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

88.0% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Nuvalent beats Day One Biopharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Day One Biopharmaceuticals compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Day One Biopharmaceuticals has higher revenue and earnings than Vaxcyte. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Day One Biopharmaceuticals	$158.18M	14.06	-$107.32M	-$1.03	N/A

Vaxcyte has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -67.85%. Day One Biopharmaceuticals' return on equity of -23.43% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Day One Biopharmaceuticals	-67.85%	-23.43%	-20.69%

Vaxcyte has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Day One Biopharmaceuticals has a beta of -1.74, suggesting that its share price is 274% less volatile than the broader market.

In the previous week, Vaxcyte had 6 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 6 mentions for Vaxcyte and 0 mentions for Day One Biopharmaceuticals. Vaxcyte's average media sentiment score of 0.99 beat Day One Biopharmaceuticals' score of 0.94 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Overall Sentiment
Vaxcyte	Positive
Day One Biopharmaceuticals	Positive

Vaxcyte currently has a consensus target price of $86.00, suggesting a potential upside of 58.53%. Day One Biopharmaceuticals has a consensus target price of $23.29, suggesting a potential upside of 8.15%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Vaxcyte is more favorable than Day One Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Day One Biopharmaceuticals	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vaxcyte beats Day One Biopharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Day One Biopharmaceuticals compare to Qiagen?

Qiagen (NYSE:QGEN) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Qiagen has higher revenue and earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.23	$424.88M	$1.91	17.14
Day One Biopharmaceuticals	$158.18M	14.06	-$107.32M	-$1.03	N/A

Qiagen has a net margin of 19.16% compared to Day One Biopharmaceuticals' net margin of -67.85%. Qiagen's return on equity of 14.40% beat Day One Biopharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Day One Biopharmaceuticals	-67.85%	-23.43%	-20.69%

Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Day One Biopharmaceuticals has a beta of -1.74, suggesting that its share price is 274% less volatile than the broader market.

In the previous week, Qiagen had 14 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 14 mentions for Qiagen and 0 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.94 beat Qiagen's score of 0.23 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Qiagen	Neutral
Day One Biopharmaceuticals	Positive

Qiagen currently has a consensus target price of $46.38, suggesting a potential upside of 41.68%. Day One Biopharmaceuticals has a consensus target price of $23.29, suggesting a potential upside of 8.15%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts clearly believe Qiagen is more favorable than Day One Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Day One Biopharmaceuticals	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Qiagen beats Day One Biopharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Day One Biopharmaceuticals compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Day One Biopharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	179.56	-$311.35M	-$3.57	N/A
Day One Biopharmaceuticals	$158.18M	14.06	-$107.32M	-$1.03	N/A

88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kymera Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market. Comparatively, Day One Biopharmaceuticals has a beta of -1.74, suggesting that its stock price is 274% less volatile than the broader market.

Day One Biopharmaceuticals has a net margin of -67.85% compared to Kymera Therapeutics' net margin of -611.94%. Day One Biopharmaceuticals' return on equity of -23.43% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Day One Biopharmaceuticals	-67.85%	-23.43%	-20.69%

In the previous week, Kymera Therapeutics had 11 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 11 mentions for Kymera Therapeutics and 0 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.94 beat Kymera Therapeutics' score of 0.32 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Kymera Therapeutics	Neutral
Day One Biopharmaceuticals	Positive

Kymera Therapeutics presently has a consensus target price of $118.10, suggesting a potential upside of 37.98%. Day One Biopharmaceuticals has a consensus target price of $23.29, suggesting a potential upside of 8.15%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kymera Therapeutics is more favorable than Day One Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Day One Biopharmaceuticals	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Day One Biopharmaceuticals beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Day One Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DAWN vs. The Competition

Export

Metric	Day One Biopharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.22B	$3.42B	$6.30B	$12.28B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-20.90	18.67	21.03	25.58
Price / Sales	14.06	305.47	554.66	78.88
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	5.01	6.75	9.78	6.66
Net Income	-$107.32M	$24.11M	$3.55B	$333.63M

Day One Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DAWN Day One Biopharmaceuticals	1.8223 of 5 stars	$21.53 flat	$23.29 +8.2%	+240.1%	$2.22B	$158.18M	N/A	60
IBRX ImmunityBio	3.2313 of 5 stars	$7.97 -1.8%	$14.20 +78.3%	+224.7%	$8.37B	$140.98M	N/A	590	Trending News Earnings Report Analyst Revision
NUVL Nuvalent	2.9452 of 5 stars	$102.91 -1.6%	$137.25 +33.4%	+47.3%	$8.09B	N/A	N/A	40	Trending News Earnings Report Analyst Revision
PCVX Vaxcyte	2.927 of 5 stars	$53.61 -0.7%	$86.00 +60.4%	+80.5%	$7.75B	N/A	N/A	160	Options Volume
QGEN Qiagen	4.5598 of 5 stars	$33.86 +3.8%	$46.38 +37.0%	-26.1%	$6.98B	$2.09B	17.70	5,654	Earnings Report Dividend Increase Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DAWN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Day One Biopharmaceuticals (DAWN) Competitors

DAWN vs. IBRX, NUVL, PCVX, QGEN, and KYMR

How does Day One Biopharmaceuticals compare to ImmunityBio?

Summary

How does Day One Biopharmaceuticals compare to Nuvalent?

Summary

How does Day One Biopharmaceuticals compare to Vaxcyte?

Summary

How does Day One Biopharmaceuticals compare to Qiagen?

Summary

How does Day One Biopharmaceuticals compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN vs. The Competition

Day One Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Day One Biopharmaceuticals (DAWN) Competitors

DAWN vs. IBRX, NUVL, PCVX, QGEN, and KYMR

How does Day One Biopharmaceuticals compare to ImmunityBio?

Which has more risk and volatility, DAWN or IBRX?

Which has higher valuation & earnings, DAWN or IBRX?

Is DAWN or IBRX more profitable?

Do analysts rate DAWN or IBRX?

Does the media favor DAWN or IBRX?

Do insiders and institutionals have more ownership in DAWN or IBRX?

Summary

How does Day One Biopharmaceuticals compare to Nuvalent?

Which has higher valuation & earnings, DAWN or NUVL?

Is DAWN or NUVL more profitable?

Which has more risk and volatility, DAWN or NUVL?

Does the media favor DAWN or NUVL?

Do analysts rate DAWN or NUVL?

Do insiders and institutionals have more ownership in DAWN or NUVL?

Summary

How does Day One Biopharmaceuticals compare to Vaxcyte?

Which has better earnings and valuation, PCVX or DAWN?

Is PCVX or DAWN more profitable?

Which has more volatility and risk, PCVX or DAWN?

Does the media refer more to PCVX or DAWN?

Do analysts prefer PCVX or DAWN?

Do institutionals and insiders have more ownership in PCVX or DAWN?

Summary

How does Day One Biopharmaceuticals compare to Qiagen?

Which has better earnings and valuation, QGEN or DAWN?

Is QGEN or DAWN more profitable?

Which has more volatility and risk, QGEN or DAWN?

Does the media refer more to QGEN or DAWN?

Do analysts prefer QGEN or DAWN?

Do institutionals and insiders have more ownership in QGEN or DAWN?

Summary

How does Day One Biopharmaceuticals compare to Kymera Therapeutics?

Which has preferable earnings & valuation, KYMR or DAWN?

Do insiders & institutionals have more ownership in KYMR or DAWN?

Which has more risk and volatility, KYMR or DAWN?

Is KYMR or DAWN more profitable?

Does the media prefer KYMR or DAWN?

Do analysts prefer KYMR or DAWN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN vs. The Competition

Day One Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools